GlassScriptPhysician profile
Stephen T Anderson
NPI 1467613034
$5,727.84
in general payments reported to CMS, 2019-2025
52 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $325 · 2021: $137 · 2022: $266 · 2023: $1,330 · 2024: $2,194 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,071 · Travel and Lodging: $456 · Education: $21.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,071.11 |
| Travel and Lodging | $455.61 |
| Education | $21.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $613.49 | 2019-2025 | |
| Relievant Medsystems, INC. | $512.06 | 2023 | Intracept |
| Boston Scientific Corporation | $496.75 | 2024 | Intracept |
| Pfizer INC. | $452.48 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $364.32 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astellas Pharma US INC | $348.36 | 2020-2024 | Padcev |
| Janssen Biotech, INC. | $312.17 | 2019-2025 | Tecvayli, Talvey, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $283.14 | 2021-2025 | Opdivo, Opdualag |
| Amgen INC. | $248.70 | 2019-2023 | Lumakras |
| Gilead Sciences, INC. | $149.84 | 2023-2025 | Trodelvy |
| Array Biopharma INC | $141.46 | 2021-2025 | Lorbrena, Mektovi, Braftovi |
| Celgene Corporation | $123.22 | 2022-2025 | Opdualag, Reblozyl |
| Shield Therapeutics INC | $113.17 | 2024 | |
| Seagen INC. | $109.29 | 2020-2023 | Padcev, Adcetris |
| Glaxosmithkline, LLC. | $108.47 | 2023-2025 | Zejula |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.